https://scholars.lib.ntu.edu.tw/handle/123456789/616203
標題: | 2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes | 作者: | Chiang, Chern En Ueng, Kwo Chang Chao, Ting Hsing Lin, Tsung-Hsien Wu, Yih Jer Wang, Kang Ling Sung, Shih Hsien Yeh, Hung I. Li, Yi Heng Liu, Ping Yen Chang, Kuan Cheng Shyu, Kou Gi Huang, Jin Long Tsai, Cheng Dao Hung, Huei Fong Liu, Ming En Chao, Tze Fan Cheng, Shu Meng Cheng, Hao Min Chu, Pao Hsien Yin, Wei Hsian YEN-WEN WU WEN-JONE CHEN Lai, Wen Ter Lin, Shing Jong Yeh, San Jou HWANG, JUEY-JEN Hou, Charles Jia Yin |
關鍵字: | antidiabetic agents | chronic kidney disease | heart failure | Taiwan Society of Cardiology | type 2 diabetes | 公開日期: | 1-九月-2021 | 卷: | 1 | 期: | 2 | 來源出版物: | JACC: Asia | 摘要: | Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/616203 | ISSN: | 27723747 | DOI: | 10.1016/j.jacasi.2021.08.003 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。